FDA grants Prescient Therapeutics (ASX:PTX) broad orphan drug status for PTX-100 cancer treatment
Oncology company Prescient Therapeutics (PTX) has been granted broad orphan drug designation…
Change | ||
S&P/ASX Sm. Ords. | |||
All Ordinaries | |||
S&P/ASX 100 |